Multiple myeloma is an incurable disease characterized by the proliferation of malignant
plasma cells in the bone marrow. Daratumumab (DARA), a monoclonal antibody that targets …

Background: Daratumumab (DARA), an IgG1κ human monoclonal anti-CD38 antibody, is
used for the treatment of refractory myeloma for example. Binding of DARA to CD38 on red …

Background Daratumumab (DARA) is a monoclonal antibody for treatment of plasma cell
myeloma targeting CD38, a surface molecule expressed on plasma cells and red blood cells …

Daratumumab, a monoclonal antibody therapeutic, is highly efficacious and widely used in
all stages of multiple myeloma and amyloidosis and has promising activity in other …

Daratumumab is a CD38-directed antibody increasingly used for the treatment of adult
patients with multiple mieloma. The membrane of red blood cells express CD38 and thus …

In recent years, the anti‐CD38 monoclonal antibody daratumumab (Darzalex; Janssen‐
Cilag Pty Ltd) has been shown to be highly efficacious in relapsed and refractory multiple …

Background: The anti-CD38 antibody daratumumab is a common multiple myeloma
treatment. As the erythrocyte's membrane expresses CD38, Daratumumab-treated samples …

Daratumumab (DARA) may interfere with immunohematology tests by binding to
endogenous CD38 present on the surface of the red blood cells. DARA was Food and Drug …

Daratumumab (DARA), a drug used to treat patients with multiple myeloma, causes
interference in pre-transfusion testing. Samples from patients receiving DARA exhibit …

Background Anti‐CD38 antibodies such as daratumumab (DARA) are critical therapies for
multiple myeloma and other diseases. Unfortunately, anti‐CD38 antibodies cause …